Academic Rank:
Professor Emeritus
BC Centre for Disease Control

Academic background

  • Fellow of the Canadian College of Microbiologists, 2000-present
  • PhD, The University of British Columbia, Microbiology. 1973
  • MSc, McMaster University, Biology. 1970
  • BSc, McMaster University, Chemistry. 1967


  • D.M. Skowronski, C. Chambers, S. Sabaiduc, G. De Serres, J.A. Dickinson, A.L. Winter, K. Fonseca, J. B. Gubbay, H. Charest, M. Petric, M. Krajden, S.M. Mahmud, P. Van Caeseele, T.L. Kwindt, A. Eshaghi, N. Bastien, Y. Li. . Interim estimates of 2013-2014 vaccine effectiveness against influenza A(H1N1)pdm09 from Canada’s sentianl surveillance network, January 2014. Eurosurveillance, Volume 19, Issue 5, 06 February 2014.
  • D.M. Skowronski, M-E. Hamelin, G. De Serres3, N.Z Janjua1, G. Li, S. Sabaiduc, X. Bouhy, C. Couture , A. Leung, D. Kobasa, C. Embury-Hyatt, E. de Bruin, R. Balshaw, S. Lavigne, M. Petric, M. Koopmans, G. Boivin. Randomized Controlled Ferret Study to Assess the Direct Impact of 2008–09 Trivalent Inactivated Influenza Vaccine on A(H1N1)pdm09 Disease Risk. PLoS ONE 2014; 9(1): e86555. doi:10.1371/journal.pone.0086555 Published (January 27, 2014).
  • D.M Skowronski, N.Z. Janjua, S. Sabaiduc, G. De Serres, A.L. Winter, J.B Gubbay, J.A. Dickinson, K. Fonseca, H. Charest, N. Bastien, Y. Li, T.L. Kwindt, S.M. Mahmud, P. Van Caeseele, M. Krajden, M. Petric. . Influenza A/subtype and B/lineage effectiveness estimates for the 2011-12 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. J Infect Dis. 2014 Jan 19. [Epub ahead of print].
  • M. Murti, M. Krajden, M. Petric, J. Hiebert, F. Hemming, B. Hefford, M. Bigham, P. Van Buynder. Case of vaccine-associated measles five weeks post-immunisation, British Columbia, Canada, October 2013. Euro Surveillance 2013;18(49):pii=20649. Available online.
  • M. Krajden, D. Cook, A. Yu, R. Chow, Q. Su, W. Mei, S. McNeil, D. Money, M. Dionne, J. Palefsky, K. Karunakaran, T. Kollmann, G. Ogilvie, M. Petric, S. Dobson. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial. Vaccine. 2013 Sep 18. pii: S0264-410X(13)01234-6. doi: 10.1016/j.vaccine.2013.09.007. [Epub ahead of print].
  • D.M. Skowronski, F.S. Moser, N.Z. Janjua, B. Davoudi, K.M. English, D. Purych, M. Petric, B. Pourbohloul. H3N2v and other influenza epidemic risk based on age-specific estimates of sero-protection and contact network interactions. PLoS ONE 2013; 8:1-10 (e54015).
  • J-H. Kim, R.. Resende, T. Wennekes, H.M Chen, N. Bance, S. Buchini, A.G. Watts, P. Pilling, V.A. Streltsov, M. Petric, R. Liggins, S. Barrett, J.L. McKimm-Breschkin, M. Niikura, S.G. Withers. Mechanism-based covalent neuraminidase inhibitors with broad spectrum influenza antiviral activity. Science. 2013;340:71-5.
  • T.F. Hatchette, S.J. Drews, N. Bastien, Y. Li , G. German, N. Antonishyn, H. Charest, T. Mazzulli, K. Fonseca, M. Krajden, M. Petric, K. Dust, J.J. Leblanc. Detection of Influenza H7N9: All Molecular Tests are Not Equal.J Clin Microbiol. 2013;51:3835-3838.
  • C.A. Thomson, Y. Wang, L.M. Jackson, M. Olson, W. Wang, A. Liavonchanka, L. Keleta, V. Silva, S. Diederich, R B. Jones, J. Gubbay, J. Pasick, M. Petric, F. Jean, V.G. Allen, E.G. Brown, J.M. Rini, J.W. Schrader. Pandemic H1N1 influenza infection and vaccination in humans induces cross-protective antibodies that target the hemagglutinin stem. Frontiers in Immunology 2012;3:87.
  • Janjua NZ, Skowronski DM, Hottes TS, Osei W, Adams E, Petric M, Lem M, Tang P, De Serres G, Patrick DM, Bowering D. Transmission dynamics and risk factors for pandemic H1N1-related illness: outbreak investigation in a rural community of British Columbia, Canada. Influenza Other Respi Viruses. 2012 Mar 2. doi: 10.1111/j.1750-2659.2012.00344.x.
Primary Research Area
Infectious Diseases and Immunopathology

Research Interest

  • Diagnostic virology
  • Influenza serology
  • Human Papilloma virus serology